PD-L1 expression in gastric carcinoma – a biomarker for immunotherapy
Keywords:PD-L1, gastric cancer, checkpoint inhibitor, immunotherapy
Introduction and Aim: Immunotherapy is now being widely used for targeted therapy in several cancers. The PD-1/ PD-L1 (programmed cell death receptor/programmed cell death ligand) axis inhibits the expansion of tumour specific T cells and prevents the immune response against tumours. PD-L1 expression is seen in many cancers including gastric carcinomas and anti PDL1 antibodies are being used to produce tumour regression. This study was done to evaluate PD-L1 expression in gastric carcinomas and correlate this with the different histological types, grades and stages of these tumours
Materials and Methods: In this study, 50 cases of gastric adenocarcinoma were analysed for PD-L1 expression using immunohistochemistry. PD-L1 expression was correlated with histopathological factors including histological type, differentiation, grade and stage using statistical methods.
Results: A positive PD-L1 expression was observed in 52% of the cases. A positive correlation between PD-L1 positivity and tumour depth to which the tumour was invading the stomach was observed. No correlation was noted with expression of PD-L1 and histological type, differentiation, histological grade and presence/absence of nodal metastasis.
Conclusion: PD-L1 expression was seen in more than half of the patients in our study. Hence it is suggested that anti PD-L1 inhibitors can be used as an adjunct in the treatment of gastric cancers, especially those with a greater depth of invasion.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer Journal for Clinicians. 2018 Nov;68(6):394-424.
Etemadi, A., Safiri, S., Sepanlou, S.G., Ikuta, K., Bisignano, C., Shakeri, R., et al., The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet gastroenterology & hepatology. 2020 Jan 1;5(1):42-54.
Nandi, A., Biswas, P.K., Kar, M., Sinha, S.K. Clinicopathological profile of gastric cancer in a tertiary care hospital in Eastern India: a prospective 2 year study. Clinical Cancer Investigation Journal. 2014 Jan 1;3(1):14.
Yang, L., Wang, Y., Wang, H. Use of immunotherapy in the treatment of gastric cancer. Oncology Letters. 2019 Dec 1;18(6):5681-5690.
Abozeid, M., Rosato, A., Sommaggio, R. Immunotherapeutic strategies for gastric carcinoma: A review of preclinical and clinical recent development. BioMed Research International. 2017 Jan 1;2017. Article ID 5791262
Rangel-Sosa, M.M., Aguilar-Córdova, E., Rojas-Martínez, A. Immunotherapy and gene therapy as novel treatments for cancer. Colombia Médica. 2017 Sep;48(3):138-147.
Waldman, A.D., Fritz, J.M., Lenardo, M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020 20:1-8.
Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol.2016;13:273-290.
Papaioannou, N.E., Beniata, O.V., Vitsos, P., Tsitsilonis, O., Samara, P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4:261
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al., Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine. 2015 Jun 25;372(26):2521-32.
Lynch, D., Murphy, A. The emerging role of immunotherapy in colorectal cancer. Ann Transl Med. 2016;4(16) :1-14.
Pardol, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2016;12(4):252 -264.
Kwon, M.J., Kim, K.C., Nam, E.S., Cho, S.J., Park, H.R., Min, S.K., et al., Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget. 2017;8(47):82399.
Kulangara, K., Hanks, D.A., Waldroup, S., Peltz, L., Shah, S., Roach, C., et al., Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. Journal of Clinical Oncology. 2017; 35(15).
Kulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., et al., Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Archives of pathology & laboratory medicine. 2019;143(3):330-337.
Mokhtari, R.B., Homayouni, T.S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., et al., Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.
Kim, J.H., Kim, S.Y., Shin, E.Y., Jung, J.H., Choi, H.J., Jun, K.H. Expression patterns of programmed death 1 and programmed death 1 ligand 1 on T cells in gastric cancer. Oncology letters. 2019;18(3):2661-2669.
Park, Y., Koh, J., Na, H.Y., Kwak, Y., Lee, K.W., Ahn, S.H., et al., PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2020;52(3):661.
Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology. 2016;27(1):147-153.
Liu, X., Choi, M.G., Kim, K., Kim, K.M., Kim, S.T., Park, S.H., et al., High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathology-Research and Practice. 2020;216(4):152881.
Huang, K.H., Chen, M.H., Fang, W.L., Lin, C.H., Chao, Y., Lo, S.S., et al., The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers. 2020;12(8):2318.
Chen, M.H., Fang, W.L., Hung, Y.P., Chao, Y. Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. Journal of the Chinese Medical Association. 2020;83(7):624-625.
Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., et al., PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PloS one. 2017;12(8):e0182692.
Yamashita, K., Iwatsuki, M., Harada, K., Eto, K., Hiyoshi, Y., Ishimoto, T., et al., Prognostic impacts of the combined positive score and the Tumour proportion score for programmed death ligand?1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23:95-104.
Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J, Tokunaga T, Nakao T, et al., Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric cancer. 2016;19(2):466-471.
How to Cite
Copyright (c) 2022 Biomedicine
This work is licensed under a Creative Commons Attribution 4.0 International License.